Hepalink (Hong Kong) Limited announced that it will receive $20 million in an equity round of funding from returning investor Shenzhen Hepalink Pharmaceutical Co., Ltd. on January 23, 2016. Post transaction, the investor will maintain its stake at 100% in the company. The transaction was approved at the 19th meeting of the 3rd directorate and 14th meeting of the 3rd supervisory board of the investor.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.67 CNY | -0.69% |
|
-3.77% | -26.09% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.09% | 1.58B | |
+20.76% | 43.77B | |
+28.00% | 22.83B | |
+20.25% | 15.56B | |
+18.82% | 14.34B | |
+55.83% | 12.96B | |
-0.05% | 6.79B | |
-12.70% | 6.41B | |
-8.87% | 5.73B | |
+14.65% | 5.69B |
- Stock Market
- Equities
- 002399 Stock
- News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Hepalink (Hong Kong) Limited announced that it expects to receive $20 million in funding from Shenzhen Hepalink Pharmaceutical Co., Ltd..